

## **Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies**

Nicole A. Doria-Rose<sup>1\*</sup>, Xiaoying Shen<sup>2</sup>, Stephen D Schmidt<sup>1</sup>, Sijy O'Dell<sup>1</sup>, Charlene McDanal<sup>2</sup>, Wenhong Feng<sup>2</sup>, Jin Tong<sup>2</sup>, Amanda Eaton<sup>2</sup>, Maha Maglinao<sup>3</sup>, Haili Tang<sup>2</sup>, Robert L. Atmar<sup>4</sup>, Kirsten E. Lyke<sup>5</sup>, Lingshu Wang<sup>1</sup>, Yi Zhang<sup>1</sup>, Martin R Gaudinski<sup>1</sup>, Walker P Black<sup>1</sup>, Ingelise Gordon<sup>1</sup>, Mercy Guech<sup>1</sup>, Julie E Ledgerwood<sup>1</sup>, John N Misasi<sup>1</sup>, Alicia Widge<sup>1</sup>, Paul C. Roberts<sup>6</sup>, John Beigel<sup>6</sup>, Bette Korber<sup>7</sup>, Rolando Pajon<sup>3</sup>, John R. Mascola<sup>1</sup>, David C. Montefiori<sup>2\*</sup>

<sup>1</sup>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; <sup>2</sup>Department of Surgery, Duke University Medical Center, Durham NC 27710; <sup>3</sup>Moderna, Inc., Cambridge, MA; <sup>4</sup>Departments of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX 77030; <sup>5</sup>Center for Vaccine Development and Global Health collaborating with the Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201; <sup>6</sup>Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; <sup>7</sup>Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545

\*Corresponding authors

Abstract:

The Omicron variant of SARS-CoV-2 is raising concerns because of its increased transmissibility and potential for reduced susceptibility to antibody neutralization. To assess the potential risk of this variant to existing vaccines, serum samples from mRNA-1273 vaccine recipients were tested for neutralizing activity against Omicron and compared to neutralization titers against D614G and Beta in a pseudovirus assay in two different laboratories. Omicron was 49-84-fold less sensitive to neutralization than D614G and 5.3-6.2-fold less sensitive than Beta when assayed with serum samples obtained 4 weeks after 2 standard inoculations with 100 µg mRNA-1273. A 50 µg boost increased Omicron neutralization titers and may substantially reduce the risk of symptomatic vaccine breakthrough infections.

Text:

Over the last two years, the COVID-19 pandemic has produced successive waves of SARS-CoV-2 variants of concern (VOCs) that outcompete earlier variants, escape therapeutic antibodies, and demonstrate partial resistance to neutralizing antibodies induced by natural infection and vaccination. The earliest variant carried a single spike mutation, D614G, providing a fitness advantage for transmission and rapidly replacing the ancestral virus as the dominant pandemic variant by May, 2020 (1). Importantly, D614G was dominant over the period of time when the Moderna mRNA-1273 vaccine demonstrated 94% efficacy in preventing symptomatic COVID-19 in the Coronavirus Efficacy (COVE) phase 3 trial (2, 3), making D614G spike protein a primary reference standard. D614G spike binding and neutralizing antibodies also correlated with vaccine efficacy in the COVE study (4), further strengthening the utility of this spike as a reference standard. Notably, D614G is one of the most neutralization-sensitive forms of the virus known to date (5). The Alpha variant approached dominant status by early 2021 and was soon surpassed by the Delta variant, which has dominated the pandemic since mid-2021. Alpha and Delta were modest neutralization escape variants, being 2-3 fold less susceptible than D614G to neutralization by mRNA-1273 vaccine-induced antibodies (5) and having little impact on mRNA-1273 vaccine efficacy (6). Other variants caused transient regional outbreaks but

were unable to compete on a global scale. Among the latter, the Beta variant that circulated in South Africa in late 2020 to mid-2021 is among the least neutralization-sensitive variants characterized to date (5) but nonetheless remains susceptible to mRNA vaccines with only a modest reduction in efficacy, especially against serious illness and death (7).

The Omicron variant that was first identified in South Africa in November 2021 is raising concerns because of its increased transmissibility and potential for reduced susceptibility to antibody neutralization attributed to the presence of a large number of spike mutations, including 15 mutations in the receptor binding domain (RBD) that is the major target for neutralizing antibodies (8, 9). To assess the potential risk of this variant to existing vaccines, identical serum samples from participants who received two standard inoculations of mRNA-1273 (100 µg) in the COVE study were tested for neutralization of Omicron in a lentivirus-based pseudovirus assay (4) in two independent laboratories: The Vaccine Research Center (VRC lab) in the National Institutes of Health (NIH), and Duke University Medical Center (Duke lab). One subset of samples from the COVE study was pre-selected as having high titers of neutralizing antibodies against D614G to enable detection of a wide range of titer reductions against Omicron. A second subset of COVE samples having moderate titers against D614G was pre-selected to avoid potential bias of high titer sera. Both laboratories assayed D614G and Beta as comparators.

Both laboratories also tested serum samples obtained from participants who received two inoculations of mRNA-1273 (100 µg) under Emergency Use Authorization (EUA) and later received a 50 µg boost of mRNA-1273, although here the two laboratories assayed samples from different subjects. The VRC lab tested serum samples from participants who received a third dose at 9 months after the second dose, all under EUA (VRC200 protocol). The Duke lab tested serum samples from a clinical study (NIAID heterologous boost study DMID 21-0012) designed to assess a vaccine boost at least 4 months after primary EUA-dosed vaccine recipients. The latter set specifically included the highest D614G responders.

The main purpose of this study was to gain an early understanding of the extent by which Omicron escapes vaccine-elicited neutralizing antibodies in comparison to D614G and Beta. The study was not designed to determine the full spectrum of vaccine-elicited neutralizing antibodies against Omicron. The Omicron spike in this study contained mutations A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, +214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F. The Beta variant contained spike mutations L18F, D80A, D215G, Δ242-244, R246I, K417N, E484K, N501Y and A701V.

Compared to D614G, ID50 geometric mean titers (GMTs) after 2 doses of vaccine were 84-fold and 49-fold lower against Omicron in the VRC and Duke laboratories, respectively (Fig 1). This is a substantial decrease compared to the 13.6- and 9.2-fold lower ID50 GMTs, respectively, against Beta. An approximate 12-fold improvement in Omicron neutralization was seen after the 50 µg boost such that the variant was now only 6.5- and 4.2-fold less neutralization-susceptible, respectively, than D614G (Fig 1). A post-boost improvement in neutralization also was seen for Beta (3.4- and 2.6-fold less susceptible, respectively, than D614G). Thus, the boost provided improvement in neutralization of both the Omicron and Beta variants. Minor differences in titer reductions between the two laboratories may be explained by sample sets that were not completely identical (see Fig 1 legend).


In a separate analysis, sequential serum samples from the 7 participants who were vaccinated and boosted under EUA were tested against D614G, Beta and Omicron. These samples were obtained 2 weeks-post second dose (already assayed above), pre-boost, and 2 weeks post-boost. Two participants were infected 5-6 months after the second dose (prior to boost) at a time when Alpha and Delta were dominant variants in the USA. ID50 titers 2 weeks after the second dose were highest against D614G and lowest against Omicron, where titers against Omicron were 35.1-fold lower and titers against Beta were 8.9-fold lower than D614G (Fig 2). Titers for the 5 uninfected participants decreased substantially by the day of boosting and rose sharply 2 weeks post-boost to titers exceeding those after the second dose; this was true for all three variants. The increase in ID50 GMT post-boost compared with a post-second dose was 12.6-fold for Omicron and 6.7-fold for Beta in these 5 participants. In contrast to the dramatic reduction in titers seen after the second dose, the post-boost ID50 GMT against Omicron showed a more modest 6.5-fold reduction compared to D614G, and the post-boost titers against Beta showed a 3.4-fold reduction compared to D614G, for all 7 participants combined. Results for the two participants who were infected between dose 2 and the boost demonstrate that infection with an earlier variant can enhance the vaccine-response to all three variants, and that additional vaccine boosting can further increase this response (Fig 2).


Together, these results suggest that neutralizing titers to Omicron are 49-84 times lower than neutralization titers to D614G after 2 doses of mRNA-1273, which could lead to an increased risk of symptomatic breakthrough infections. However, a booster dose of mRNA-1273 increases Omicron neutralization titers and may substantially reduce this risk.

This study has several limitations: 1) relatively small sample sets that do not reflect the complete range of neutralization titers in diverse demographic groups of individuals, 2) limited longitudinal data, 3) lack of data on the durability of Omicron neutralizing antibody responses post-boost, and 4) lack of live virus neutralization data. Additional work is in progress to address these limitations. The current study design permitted a preliminary assessment of the potential of Omicron to evade mRNA-1273-elicited neutralizing antibodies after 2 and 3 vaccine inoculations.

#### Acknowledgements:

We are very grateful to the many study participants who donated specimens for this study. We thank Obrimpong Amoah-Awua, Man Chen, Wing-Pui Kong, Kwanyee Leung, Allen Mueller, Wei Shi, Eun Sung Yang, Tongqing Zhou, and the VRC200 Study Team of the VRC Clinical Trials program for technical assistance. This study received support from NIH 75N93019C00050 (DCM, XS), NIH U19 AI142790 (BK), NIH UM1AI148684 (LG), NIH UM1AI148575 (RLA), NIH UM1 AI148689 (KL), Moderna, Inc., and the Intramural Research Program of the Vaccine Research Center, NIAID, NIH (NADR, SDS, SOD, YZ, MRG, WPB, IG, MG, JEL, and JRM).





## References:

1. Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. *Cell* 2020; 182(4): 812-827.e19.
2. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 2021; 384:403-416.
3. El Sahly, H.M., et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *N Engl J Med* 2021; 385:1774-1785.
4. Gilbert PB, Montefiori DC, McDermott AB, et al., Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science* 2021; 10.1126/science.abm3425.
5. Pegu A, O'Connell SE, Schmidt SD, et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. *Science* 2021; 373:1372–1377.
6. Bruxvoort KJ, Sy LS, Qian L, et al. Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants. medRxiv preprint doi: <https://doi.org/10.1101/2021.09.29.21264199>
7. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. *N Engl J Med* 2021; 385:187-189.
8. World Health Organization. 2021. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. [https://www.who.int/news/item/26-11-2021-classification-of-omicron-\(b.1.1.529\)-sars-cov-2-variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern).
9. Hastie KM, Li H, Bedinger D, et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. *Science* 10.1126/science.abh2315 (2021).